Investor Presentaiton

SELECT TRIALS - REMTERNETUG Lilly Primary Completion Completion Study Indication* Title Phase Patients Primary Outcome** NCT05463731 Alzheimer A Study of Remternetug (LY3372993) in Participants With Disease Alzheimer's Disease (TRAILRUNNER-ALZ 1) 3 600 Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo Oct 2025 Oct 2026 * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use Source: clinicaltrials.gov, July 24, 2023 2023 Q2 EARNINGS 45

View entire presentation